OR WAIT null SECS
August 20, 2024
Fasenra, which has been approved since 2019 in the United States in a pre-filled, single-use auto-injector form that can be administered either in a doctor’s office or at home, is now approved in China for age 12 and up.
Approximately 15% of all lung cancers diagnosed in the US are of the small-cell variety, and of those, 70% are considered extensive-stage.
August 19, 2024
NexoBrid, a topically administered biological product, is now authorized for use in all age groups in the United States, European Union, and Japan.
Breyanzi demonstrated an overall high response rate in adults with relapsed or refractory follicular lymphoma in a Phase II study.
August 15, 2024
Imfinzi may be used alone, or with chemotherapy in tandem with the other approved treatment, Lynparza.
August 14, 2024
Yorvipath is a prodrug of parathyroid hormone (PTH) (1-34), designed to be administered once daily to provide continuous exposure to released PTH.
AstraZeneca and Daiichi Sankyo first entered into an agreement to develop Enhertu in March 2019, and the antibody-drug conjugate has since been approved for various groups in more than 65 countries.
August 13, 2024
The epinephrine nasal spray was approved for the emergency treatment of type 1 allergic reactions in adults and children.
August 08, 2024
The reopening of comments addresses the addition of a warning to consumers that acetaminophen may cause skin irritation characterized by reddening, blisters, and rashes.
August 05, 2024
Synovial sarcoma is a rare form of cancer impacting about 1000 adults in the United States each year, most of them men in their 30s or younger.